Cencora has put up a powerful long term share price performance, yet the current US$330.84 price invites a sharper question. Are the cash flows behind the business strong enough, and predictable enough, to make that level look well supported?
-
Over the past 5 years the stock is up 172.6%, which puts a lot of weight on whether the underlying cash generation matches the market's enthusiasm.
-
The planned US$2.4b purchase of American Oncology Network can reshape how quickly Cencora converts its oncology footprint into cash, and how much capital it needs to keep investing in community cancer care.
-
Prefer to judge Cencora on earnings? See
The issue now is whether Cencora's current share price is aligned with the intrinsic value suggested by its cash flows under a Discounted Cash Flow (DCF) lens.
If you want a reference point for Cencora's oncology and cash flow story, try lining it up against other healthcare names in 34 healthcare AI stocks.
Is Cencora a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here estimates what Cencora might be worth based on the cash it can return to shareholders over time. On the numbers, the latest twelve month free cash flow sits at about $4...